微泰医疗
MICROTECH MEDICAL

MicroTech Medical (Hangzhou) Co., Ltd.
微泰醫療器械（杭州）股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 2235)

VOLUNTARY ANNOUNCEMENT
REGISTRATION APPROVAL BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF THE COMPANY'S CONTINUOUS GLUCOSE MONITORING SYSTEM

This announcement is published by MicroTech Medical (Hangzhou) Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis, for the purpose of keeping the shareholders and potential investors of the Company informed of the latest development of the Group.

The board (the "**Board**") of directors (the "**Directors**", and each a "**Director**") of the Company is pleased to announce that the new-generation sensor-separated continuous glucose monitoring system of the Company, AiDEX G9 (the "**Product**"), has recently received marketing approval from the National Medical Products Administration for commercialisation in China. Compared with the first-generation sensor-separated product, AiDEX G9 has achieved an innovative transformation in its technical architecture, together with comprehensive upgrades in terms of its size, portability and wearing comfort, offering diabetic patients a lighter and more comfortable experience in glucose management.

China is one of the largest diabetes markets in the world. According to the IDF Diabetes Atlas 2025 published by the International Diabetes Federation (the "**IDF**"), there were approximately 148 million adults aged 20–79 living with diabetes in China in 2024, ranking first globally. Meanwhile, the number of people with prediabetes in China reached 274 million, representing a substantial population at high risk of developing diabetes. The approval of the Product will further enrich the Group's product pipeline, expand its user coverage, user coverage, and help the Group seize the development opportunities in the Chinese market, thereby consolidating and enhancing the Group's market position and competitive advantages in the field of continuous glucose monitoring.

Going forward, the Company will continue to focus on the global development of diabetes monitoring, treatment and management solutions, and persistently drive technological and product innovation in related fields.

The Company reminds the investors that the production, sales and the resulting income of the above-mentioned product are affected by many factors such as market changes. Shareholders and potential investors of the Company are requested to exercise caution when dealing with the shares of the Company.

By order of the Board
MicroTech Medical (Hangzhou) Co., Ltd.
Zheng Pan
Chairman of the Board

Hangzhou, the PRC, September 7, 2026

As at the date of this announcement, the executive Directors are Dr. Zheng Pan, Dr. Yu Fei, Dr. Shi Yonghui and Ms. Liu Xiu; the non-executive Directors are Mr. Mao Shuo and Ms. Gao Yun; and the independent non-executive Directors are Dr. Li Lihua, Ms. Wang Chunfeng, Mr. Ho Kin Cheong Kelvin and Dr. Cheng Hua.